(Total Views: 337)
Posted On: 02/16/2021 11:59:50 PM
Post# of 653
$RLFTF "Thought Post Buffet"
Aside from the cost considerations, the improved time out of ICU thanks to this drug will definitely lead to lower incidence of healthcare acquired secondary infections like MRSA. The longer people stay in ICUs the more likely they are to acquire a secondary infection. - frenchman
Had a thought today... Not only is a reduction in hospital day stays so important because of the long term effect and damage that being ventilated can cause... but what about insurance companies? Shorter hospital stays drastically reduces medical costs and could save insurance companies billions!
So, I would think that they would be a huge advocate of RLF-100. One would also think that they have friends in high places to push for the emergency use.
- bob 1968
----
AMAZING NEUROPEPTIDE
Neurodegenerative disorders (NDDs) are characterized by neuronal death in the brain. The mechanism of the neuronal death is too complicated to be fully understood, although in many NDDs, aging and neurotoxins are known risk factors.
In the central and peripheral nervous system, vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide, is released to support neuronal survival in both physiological and pathological condition. VIP can inhibit the neurodegeneration induced by the loss of neurons.
The indirect protection effect is mainly mediated by glial cells through the production of neurotrophic factor(s) and inhibition of proinflammatory mediators.
By remolding the structure and improving the transfer efficiency of VIP, its nerve protective function could be further improved.
Its neuroprotective action and efficacy in inhibiting a broad range of inflammatory responses make VIP or related peptides becoming a novel therapeutic method to NDDs. In this review, we aim to summarize the relationship between VIP and NDDs.
https://www.researchgate.net/publication/3094..._disorders
The global neurodegenerative disorder therapeutics market was worth $13.35 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 8.12% and reach $18.23 billion by 2023.
https://www.globenewswire.com/news-release/20...dings.html
- changes_iv
Aside from the cost considerations, the improved time out of ICU thanks to this drug will definitely lead to lower incidence of healthcare acquired secondary infections like MRSA. The longer people stay in ICUs the more likely they are to acquire a secondary infection. - frenchman
Had a thought today... Not only is a reduction in hospital day stays so important because of the long term effect and damage that being ventilated can cause... but what about insurance companies? Shorter hospital stays drastically reduces medical costs and could save insurance companies billions!
So, I would think that they would be a huge advocate of RLF-100. One would also think that they have friends in high places to push for the emergency use.
- bob 1968
----
AMAZING NEUROPEPTIDE
Neurodegenerative disorders (NDDs) are characterized by neuronal death in the brain. The mechanism of the neuronal death is too complicated to be fully understood, although in many NDDs, aging and neurotoxins are known risk factors.
In the central and peripheral nervous system, vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide, is released to support neuronal survival in both physiological and pathological condition. VIP can inhibit the neurodegeneration induced by the loss of neurons.
The indirect protection effect is mainly mediated by glial cells through the production of neurotrophic factor(s) and inhibition of proinflammatory mediators.
By remolding the structure and improving the transfer efficiency of VIP, its nerve protective function could be further improved.
Its neuroprotective action and efficacy in inhibiting a broad range of inflammatory responses make VIP or related peptides becoming a novel therapeutic method to NDDs. In this review, we aim to summarize the relationship between VIP and NDDs.
https://www.researchgate.net/publication/3094..._disorders
The global neurodegenerative disorder therapeutics market was worth $13.35 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 8.12% and reach $18.23 billion by 2023.
https://www.globenewswire.com/news-release/20...dings.html
- changes_iv
(0)
(0)
$MJ
